Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this dose-escalation study is to assess the safety and tolerability of
treatment with Chiauranib and Chidamide administered orally over a range of doses in patients
with relapsed or refractory non-Hodgkin's lymphoma, in the meantime, exploring the
pharmacodynamic profile and latent biomarkers accompany with Chiauranib and Chidamide , as
well as the relevancy of which and clinical benefit.